Mologic seeks alternative to “relentless profiteering” of medical industry by providing affordable medical technology in poorer countries in £30m acquisition backed by Gates Foundation, Soros Economic Development Fund and others.
Leading scientists at Imperial College London developing a Covid-19 vaccine have chosen a social enterprise structure for “maximum flexibility” and to remain affordable to the world’s poorest.
How can corporates, and their foundations, drive systemic change? Daniel Nowack shares insights from research at Yunus Social Business – with examples of how some of the world's biggest commercial names are deploying more than just cash.
